title: Choroidal melanoma: a review of the experience of the Sydney Eye Hospital Professorial Unit 1979-1995.
abstract: OBJECTIVE
  This study examines 90 patients presenting with choroidal or ciliochoroidal melanoma to the Professorial Unit at the Sydney Eye Hospital. The indications for treatment, and the outcome for the eye and vision are presented together with an account of mortality and the incidence of metastases.
  
  
  METHODS
  A retrospective analysis of 90 choroidal melanoma patients managed by one surgeon over a 16-year period was undertaken. Initial findings, investigations performed, incidence of metastatic disease, treatment received and complication rates and mortality, where applicable, were recorded.
  
  
  RESULTS
  The group was followed for an average of 64 months (range, 5-172 months). Primary treatment was with either iodine125 (125I) brachytherapy, local excision or enucleation. Radiation retinopathy was prominent in 125I cases resulting in poor visual acuity when the tumour resided in the posterior pole. Local excision even of large tumours was effective particularly if peripheral. Overall metastatic disease was seen in 11% with 5-year survival rates for the metastatic group being 10%. Prognosis after diagnosis of metastases was poor.
  
  
  CONCLUSIONS
  Specific therapy for choroidal melanoma must relate to the size and location of the tumour at the time of diagnosis. Visual outcome relates directly to the proximity of the tumour to the optic nerve and fovea. Metastatic disease latency can be prolonged; therefore caution about prognosis is required long after therapy is given. The 5-year survival is encouraging with all forms of therapy. However, as the natural history of ocular melanoma is variable and not fully delineated it is important to monitor the effects of conservative therapy. Further long-term survival data is required to distinguish whether one form of treatment is advantageous over the others, although case-control studies are difficult for ethical and practical reasons. In this regard the Collaborative Ocular Melanoma Study (COMS) will provide further evidence for the safety and efficacy of conservative therapy with brachytherapy compared to enucleation.
authors.affiliation: Professorial Unit, Sydney Eye Hospital, New South Wales, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Reader
authors.forename: J
authors.initials: J
authors.lastname: Grigg
authors.forename: F A
authors.initials: FA
authors.lastname: Billson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia / Q000453:epidemiology; D001918:Brachytherapy / Q000379:methods; D002830:Choroid Neoplasms / Q000401:mortality / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D015353:Eye Enucleation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D008875:Middle Aged; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D014792:Visual Acuity
chemical_list: D007457:Iodine Radioisotopes